Heart disease. Hearing loss. Addiction. Chronic pain. Alzheimer’s. ALS. These are some of the areas where Eli Lilly, flush with cash from its GLP-1 drugs, wants to make big bets.
These are the ideas that are “hiding in plain sight,” said Lilly Chief Scientific Officer Dan Skovronsky. They’re places where other pharmaceutical companies might not want to go because they’re hard problems to solve.
“As right now really the biggest health-care company in the world, probably the biggest health-care company in the world ever, we have an obligation,” Skovronsky said. “Investors have given us that vote of confidence. We see that as an obligation to invest in some of these big problems that are hiding in plain sight, to try and make a difference for the health of your community.”
Lilly’s tirzepatide, sold as Mounjaro for diabetes and Zepbound for obesity, has transformed the company. The company’s sales have grown almost 60% since Mounjaro…
